According to a study published in 2019, Canadian senior citizens often received vitamin B₁₂ as an injection in cases where oral supplementation with the biofactor, which is less expensive and more convenient for the patients, would have achieved the same success. The scientists also emphasised that almost 40% of those examined had no diagnostic evidence of vitamin B₁₂ deficiency before the injection.

According to the authors of the study, 20% of Canadian senior citizens have vitamin B₁₂ deficiency.¹ In Germany, the figures are similar: approx. one in four people over the age of 65 suffers from vitamin B₁₂ deficiency,² with the figure among senior citizens in nursing homes even being as high as 40%.³
In order to be able to detect the vitamin B₁₂ status and compensate for a deficiency by means of supplements, vitamin B₁₂ diagnostics should be integrated into everyday practice since – according to the Canadian scientists – supplementation without any proven deficiency is not only ineffective, but also causes unnecessary costs for the health care system.
 
Vitamin B₁₂ supplementation required?
The experts from the Society for Biofactors (GfB) also emphasise how important regular diagnostic checks are in order to detect vitamin B₁₂ deficiency and that the possibility of vitamin B₁₂ substitution by means of oral administration is a relief for many patients. Even in patients with absorption disorders, vitamin B₁₂ deficiency can be compensated for by high-dose oral supplementation – independently of the intrinsic factor by passive diffusion through the intestinal mucosa.⁴ Studies have also shown that oral high-dose therapy with 1,000-2,000 µg of vitamin B₁₂ is better tolerated than intramuscular injection in cases of absorption disorders.^5,6
“Only in patients with severe neurological diseases or pernicious anaemia is parenteral substitution initially necessary, and this can be continued orally,” confirmed Prof. Karlheinz Reiners, who is a neurologist and member of the Scientific Advisory Board of the Society for Biofactors.

Early diagnosis of vitamin B₁₂ deficiency is important
In practice, vitamin B₁₂ deficiency can be overlooked as it develops insidiously and initial symptoms such as tiredness, concentration problems or fatigue are non-specific. However, the disorders of erythropoiesis with the development of megaloblastic anaemia and the neurological consequences can also be associated with serious diseases.¹ While the blood count changes are characteristic and confirm the diagnosis of a deficiency, the neurological complaints are many and varied and are not always recognised as deficiency symptoms. “The early diagnosis of vitamin B₁₂ deficiency is therefore essential, not only because the neurological disorders often precede the haematological abnormalities or occur entirely without blood count changes, but also because neurological symptoms can become irreversible,” warns the medical practitioner Reiners.

Where does vitamin B₁₂ deficiency start?
Total vitamin B₁₂ serum blood levels between 200 and 1,000 ng/l are considered normal values, whereas values below 200 ng/l are proof of a definite deficiency. However, total vitamin B₁₂ is a late, comparatively insensitive and inaccurate biomarker of vitamin B₁₂ deficiency.^8,9 For blood levels between 200 and 400 ng/l it is advisable to measure holotranscobalamin (holo-TC), which reflects the status of the actual active vitamin B₁₂. Holo-TC values below 35 pmol/l indicate vitamin B₁₂ deficiency. The “grey area” in which clinical or haematological symptoms may be absent is between 36 and 55 pmol/l.⁷ Then methylmalonic acid (MMA) and homocysteine should be measured, which are two functional indicators of vitamin B₁₂ deficiency. If, in addition to a low holo-TC level, the MMA (> 300 nmol/l or > 0.4 µmol/l) and homocysteine levels are elevated (> 10 µmol/l), manifest vitamin B₁₂ deficiency is present intracellularly.

Conclusion of the Society for Biofactors
In senior citizens in particular, attention should be paid to the optimum vitamin B₁₂ status, any potential deficiency clarified diagnostically and, in the case of a positive finding, compensated for by targeted supplementation. High-dose oral vitamin B₁₂ therapy is recommended, with initial parenteral administration – which can be continued orally – only for patients with severe neurological diseases or pernicious anaemia.

Literatur:

1. Silverstein WK et al.: Prevalence of inappropriateness of parenteral vitamin B12 administration in Ontario, Canada. JAMA Intern Med 2019 Jul, 179(10): 1434-1436
2. Conzade R et al.: Prevalence and predictors of subclinical micronutrient deficiency in German older adults: results from the population-based KORA-Age Study. Nutrients 2017, 9, 1276 ff
3. Andrès E et al.: Vitamin B12 deficiency in elderly patients. CMAJ 2004, 171(3): 251-259
4. Andrès et al.: Systematic review and pragmatic clinical approach to oral and nasal vitamin B₁₂ (Cobalamin) treatment in patients with vitamin B₁₂ deficiency related to gastrointestinal disorders. J Clin Med 2018, 7 (304)
5. Bolaman Z et al.: Oral versus intramuscular cobalamin treatment in megaloblastic anemia: A single-center, prospective, randomized, open-label study. Clinical Therapeutics 2003, 25(12)
6. Vidal-Alaball JV et al.: Oral vitamin B₁₂ versus intramuscular vitamin B₁₂ for vitamin B₁₂ deficiency. Cochrane Database. Syst Rev 2005 Jul, 20(3)
7. Wolffenbuttel BHR et al.: The Many Faces of Cobalamin (Vitamin B₁₂) Deficiency. Mayo Clin Proc Inn Qual Out 2019, 3(2): 200-214
8. Herrmann W et al.: Causes and early diagnosis of vitamin B12 deficiency. Dtsch Arztebl 2008, 105(40): 680-5
9. Reiners K: Vitaminkrankheiten. In: Hoffmann GF, Grau AJ (Hrsg): Stoffwechselerkrankungen in der Neurologie. Stuttgart: Thieme, 2004, 163-176